Integrating CAR-T cells with other immunotherapies for improved efficacy in cancer patients

Chimeric Antigen Receptor (CAR) T cell therapy is a novel cum innovative treatment for cancer patients, especially the ones dealing with blood cancers. However, solid tumours remain an area where this therapy is not so effective. The challenges are antigen heterogeneity, immunosuppressive tumour microenvironment, and some unaddressed serious side effects. This study details how different immunotherapeutic approaches can be used in synergy with each other to augment efficacy of CAR-T cell-based therapy and to minimize its limitations as a standalone therapy. Our review looks at how immune checkpoint inhibitors (ICIs), cytokine-based approaches, hematopoietic stem cell transplantation (HSCT), cancer vaccines, oncolytic viruses, monoclonal antibodies, NK cell therapy, tumour-infiltrating lymphocytes, bispecific T-cell engagers (BiTEs), and oncolytic viruses (OVs) could be utilized together with CAR-T cell therapy. Reducing repressive cell populations and improving antigen presentation helps OVs modify the TME, enabling better CAR-T cell penetration and persistence. Similar to this, BiTEs deal with issues of antigen loss and relapse by increasing the number of cells that target antigens and bringing in bystander T-cells. Moreover, cytokine co-delivery and changes inside cells show promise in lowering systemic toxicity and increasing continuous CAR-T activation. Early-stage clinical trials and preclinical studies show that these combinatorial strategies may work, but there are still issues like dose-dependent toxicity, exact treatment timing, and delivery restrictions. This review highlights generally the possibilities of combinational techniques to greatly increase the efficacy and safety profile of CAR-T cell treatments, thus providing insightful information for next studies and clinical uses in cancer immunotherapy.